5-bromo-1-tosyl-1H-indole-3-carboxaldehyde | 158991-80-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-bromo-1-tosyl-1H-indole-3-carboxaldehyde
• 英文别名: 5-bromo-1-tosyl-1H-indole-3-carbaldehyde；1-(4-Methylphenylsulfonyl)-5-bromoindole-3-carboxaldehyde；5-bromo-1-(4-methylphenyl)sulfonylindole-3-carbaldehyde
• CAS: 158991-80-1
• 化学式: C₁₆H₁₂BrNO₃S
• 分子量: 378.246
• InChiKey: HXWFWQOIAAMUJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  64.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-bromo-1-tosyl-1H-indole-3-carboxaldehyde 在 (2S)-2-[二苯基[(三甲基硅酯)氧基]甲基]-吡咯烷 、 ammonium acetate 作用下， 以 二氯甲烷 为溶剂， 反应 40.0h， 生成 (S)-2-((R)-1-(5-bromo-1-tosyl-1H-indol-3-yl)-2-nitroethyl)octanal
  参考文献：
  名称：

  Organocatalytic Asymmetric Michael Addition of Aliphatic Aldehydes to Indolylnitroalkenes: Access to Contiguous Stereogenic Tryptamine Precursors

  摘要：

  Because of the importance of the indole framework and the versatile transformation of nitro and formyl groups, the efficient synthesis of optically pure 2-alkyl-3-(1H-indol-3-yl)-4-nitrobutanals, one type of tryptamine precursors are of great interest for pharmaceutical and biological research. Herein, the Michael addition of aliphatic aldehydes to indolylnitroalkenes has been developed using (S)-diphenylprolinol trimethylsilyl ether as an organocatalyst, which provides the desired optically pure syn 2-alkyl-3-(1H-indol-3-yl)-4-nitrobutanal derivatives in up to 98% yield with up to >99:1 dr and >99% ee. To show the synthetic usefulness of this methodology, optically active 2-alkyl-4-nitro-3-(1-tosyl-1H-indol-3-yl)butan-1-ol and tryptamine derivatives are readily obtained by stepwise systematic transformations.

  DOI：

  10.1021/jo3024945
• 作为产物：
  描述：

  5-溴吲哚 在 三乙胺 、 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 反应 2.25h， 生成 5-bromo-1-tosyl-1H-indole-3-carboxaldehyde
  参考文献：
  名称：

  3-吲哚基甲醇和炔烃异常形成环戊[ b ]吲哚

  摘要：

  已经报道了由3-吲哚基甲醇和炔烃酸促进的环戊[ b ]吲哚骨架的合成。整个变换表示通过重新排列而形成的正式[3 + 2]圆环。该方案对甲醇底物和炔烃显示出良好的通用性，并允许生成结构多样的环戊[ b ]吲哚。发现末端炔烃，二烷基取代的内部炔烃和具有电子不足的取代基的炔烃不适合该转化。同样，N -Ts和N -Boc基团与反应条件兼容，而N -Ac和N-Tf未能进行此反应。氯乙烯中间体的分离表明涉及乙烯基碳阳离子中间体。已经提出了一种机制，包括开环-​​闭环级联反应，然后通过螺环丁烯中间体进行1,3-吲哚迁移过程。

  DOI：

  10.1021/acs.joc.8b03027

文献信息

• Synthesis and Bioactivity Evaluation of N-Arylsulfonylindole Analogs Bearing a Rhodanine Moiety as Antibacterial Agents
  作者：Ming-Xia Song、Song-Hui Li、Jiao-Yang Peng、Ting-Ting Guo、Wen-Hui Xu、Shao-Feng Xiong、Xian-Qing Deng

  DOI：10.3390/molecules22060970

  日期：——

  the scarcity of novel agents under development, bacterial infections are still a pressing global problem, making new types of antibacterial agents, which are effective both alone and in combination with traditional antibiotics, urgently needed. In this paper, seven series of N-arylsulfonylindole analogs 5–11 bearing rhodanine moieties were synthesized, characterized, and evaluated for antibacterial

  由于细菌对抗生素的耐药性迅速增长，并且正在开发的新型药物的稀缺性，细菌感染仍然是一个紧迫的全球问题，迫切需要新型抗菌药物，无论是单独使用还是与传统抗生素联合使用都有效。在本文中，合成、表征和评估了七个系列的 N-芳基磺酰基吲哚类似物 5-11 带有罗丹宁部分的抗菌活性。根据体外抗菌结果，一半合成的化合物对四种革兰氏阳性菌显示出有效的抑制作用，MIC 值在 0.5-8 µg/mL 范围内。对于多重耐药菌株，化合物 6a 和 6c 的效力最强，MIC 值为 0.5 µg/mL，与加替沙星的活性相当，
• 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and
  申请人：Hoechst-Roussel Pharmaceuticals Incorporated

  公开号：US05360811A1

  公开（公告）日：1994-11-01

  Novel 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols of the formula RCH(OR.sup.1)CH(NR.sup.2 R.sup.3)R.sup.4 or RCH.sub.2 CR.sup.35 (NR.sup.2 R.sup.3)R.sup.4 wherein R is ##STR1## wherein R.sup.5 is CH.sub.3 (CH.sub.2).sub.m C.tbd.C, CH.sub.3 (CH.sub.2).sub.m CH.dbd.CH,CH.sub.3 (CH.sub.2).sub.m CH.sub.2 CH.sub.2, ##STR2## wherein m is 3 to 15, n is 0 to 12, and W and X are independently hydrogen, hydroxy, alkyl, alkoxy, halogen, or trifluoromethyl, ##STR3## wherein R.sup.23 loweralkyl; Z is S, O, or C.dbd.O; and A is S or O; R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.35 and R.sup.40 are as defined in the specification, the optical isomers thereof, or the pharmaceutically acceptable salts thereof, intermediates and processes for the preparation thereof, and methods of reducing inflammation and cell proliferation, and relieving memory dysfunction, and inhibiting bacterial and fungal growth are disclosed.

  1-烷基、1-烯基和1-炔基芳基-2-氨基-1,3-丙二醇的公式为RCH(OR1)CH(NR2R3)R4或RCH2CR35(NR2R3)R4，其中R是##STR1##，其中R5是CH3(CH2)mC≡C，CH3(CH2)mCH═CH，CH3(CH2)mCH2CH2，##STR2##，其中m是3到15，n是0到12，W和X独立的是氢、羟基、烷基、烷氧基、卤素或三氟甲基，##STR3##，其中R23是较低烷基；Z是S、O或C═O；A是S或O；R1、R2、R3、R4、R35和R40按说明书定义，其光学异构体，或其药物可接受的盐，中间体及其制备方法，以及用于减少炎症和细胞增殖，缓解记忆功能障碍，抑制细菌和真菌生长的方法被披露。
• [EN] N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM<br/>[FR] INDOLES N-ARYLSULFONYL-3-SUBSTITUES PRESENTANT UNE AFFINITE POUR LE RECEPTEUR DE LA SEROTONINE, METHODE DE PREPARATION ET COMPOSITION PHARMACEUTIQUE CONTENANT CES INDOLES
  申请人：SUVEN LIFE SCIENCES LTD

  公开号：WO2004048330A1

  公开（公告）日：2004-06-10

  The present invention relates to novel N-arylsulfonyl-3-substituted indole compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their geometric forms, their N-oxides, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel N-arylsulfonyl-3-substituted indoles of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, and pharmaceutically acceptable compositions containing them. This invention also relates to the process for preparing compounds of the general formula (I), pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicine. This invention also relates to the novel intermediates involved therein and process of their preparation.

  本发明涉及新型的N-芳基亚磺酰基-3-取代吲哚化合物、其衍生物、类似物、互变异构体、立体异构体、几何异构体、N-氧化物、多晶型、药物可接受的盐、药物可接受的溶剂化物以及含有它们的药物可接受组合物。本发明特别涉及具有通用公式(I)的新型N-芳基亚磺酰基-3-取代吲哚、其衍生物、类似物、互变异构体、立体异构体、多晶型、药物可接受的盐、药物可接受的溶剂化物以及含有它们的药物可接受组合物。本发明还涉及制备通用公式(I)化合物的过程、含有此类化合物的药物组合物以及此类化合物和组合物在医学中的用途。本发明还涉及其中涉及的新中间体及其制备过程。
• Organocatalytic enantioselective synthesis of C3 functionalized indole derivatives
  作者：Jasneet Kaur、Nasarul Islam、Akshay Kumar、Vimal K. Bhardwaj、Swapandeep Singh Chimni

  DOI：10.1016/j.tet.2016.10.037

  日期：2016.12

  Michael addition reaction of indolylnitroalkenes with 1,3-dicarbonyl compounds has been developed to obtain enantiomerically enriched 3-(2-nitro-1-(1-tosyl-1H-indol-3-yl)ethyl)pentane-2,4-dione derivatives in up to 98% ee using BnCPN as an organocatalyst. The transition state structure has been predicted using DFT calculation.

  已经开发了吲哚基硝基烯烃与1，3-二羰基化合物的高对映选择性迈克尔加成反应，以获得对映体富集的3-（2-硝基-1-（1-甲苯磺酰基-1 H-吲哚-3-基）乙基）戊烷-2使用BnCPN作为有机催化剂，可在高达98％ee的条件下得到1,4-二酮衍生物。已经使用DFT计算预测了过渡状态结构。
• One-pot sequential multicomponent reaction between <i>in situ</i> generated aldimines and succinaldehyde: facile synthesis of substituted pyrrole-3-carbaldehydes and applications towards medicinally important fused heterocycles
  作者：Anoop Singh、Nisar A. Mir、Sachin Choudhary、Deepika Singh、Preetika Sharma、Rajni Kant、Indresh Kumar

  DOI：10.1039/c8ra01637b

  日期：——

  An efficient sequential multi-component method for the synthesis of N-arylpyrrole-3-carbaldehydes has been developed. This reaction involved a proline-catalyzed direct Mannich reaction-cyclization sequence between succinaldehyde and in situ generated Ar/HetAr/indolyl-imines, followed by IBX-mediated oxidative aromatization in one-pot operation. The practical utility of this procedure is shown at gram-scale

  开发了一种有效的连续多组分合成N-芳基吡咯-3-甲醛的方法。该反应涉及琥珀醛和原位生成的 Ar/HetAr/吲哚基亚胺之间脯氨酸催化的直接曼尼希反应环化序列，然后在一锅操作中进行 IBX 介导的氧化芳构化。该方法的实用性以克级显示，并合成了多种生物活性稠合杂环支架，例如吡咯并喹啉、吡咯并恶二唑、二氢吡咯并喹啉和吡咯并菲啶。